Results 81 to 90 of about 1,848 (184)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

, 2017
Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with other aetiologies. The underlying CTD can influence treatment response and outcomes.
Lewis J. Rubin, Channick, Richard, Lang, Irene M., Ralph Preiss, Rubin, Lewis J., Nazzareno Galiè, Vallerie McLaughlin, Hoeper, Marius M., Gérald Simonneau, Gaine, Sean, Ghofrani, Hossein-Ardeschir, Coghlan, Gerry, Di Scala, Lilla, Tapson, Victor F., Gerry Coghlan, Lilla Di Scala, Chin, Kelly, McLaughlin, Vallerie, Sean Gaine, Richard Channick, Sitbon, Olivier, Kelly Chin, Victor F. Tapson, Irene M. Lang, Preiss, Ralph, Marius M. Hoeper, Olivier Sitbon, Galiè, Nazzareno, Simonneau, Gérald, Hossein-Ardeschir Ghofrani   +29 more
core   +1 more source

Direct prostacyclin transition in pediatric patients with pulmonary hypertension

Pulmonary Circulation
Pediatric patients with pulmonary arterial hypertension (PAH) are commonly treated with the prostacyclin analog treprostinil in IV, SQ, inhaled or oral form, or the prostacyclin receptor agonist selexipag.
Kelly Merrill, Anne Davis, Emma Jackson, Meredith Riker, Christa Kirk, Delphine Yung   +5 more
doaj   +1 more source

Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension

Background Selexipag, an oral prostacyclin receptor agonist, significantly reduced morbidity/mortality risk versus placebo for patients with pulmonary arterial hypertension (PAH) in GRIPHON.
Oudiz R. J., Elwing J., McLaughlin V. V., Galie N., Tamura Y., Fernandes C. C., Stickel S., Gaine S., Howard L., Strachan P., Stefani M., Kim N. H.   +11 more
core   +1 more source

Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension

Therapeutic Advances in Respiratory Disease
Background Selexipag, an oral IP prostacyclin receptor agonist, improves outcomes in pulmonary arterial hypertension (PAH); however, real-world hemodynamic data and the relationship between adverse events (AEs) and treatment response are limited ...
Ryotaro Asano MD, PhD, Takatoyo Kiko MD, PhD, Takanori Kawabata MS, Yuka Sano MD, PhD, Hiroyuki Endo MD, Ryo Takano MD, Shinya Fujisaki MD, Hiroya Hayashi MD, PhD, Jin Ueda MD, Akihiro Tsuji MD, PhD, Koichi Matsuoka MS, Kohji Murakami MS, Takeshi Ogo MD, PhD   +12 more
doaj   +1 more source

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study

, 2018
Background: Parenteral prostacyclin analogs that target the prostacyclin pathway have been used to treat pulmonary arterial hypertension (PAH) since the 1990s.
Lewis J. Rubin, Channick, Richard, Mclaughlin, Vallerie, Lang, Irene M., Vallerie V. McLaughlin, Ralph Preiss, Hoeper, Marius, Channick, Richard N., Rubin, Lewis J., Nazzareno Galiè, Hoeper, Marius M., Farber, Harrison W., Gérald Simonneau, Gaine, Sean, Simonneau, Gérald, Farber, Harrison, Lang, Irene, Ghofrani, Hossein-Ardeschir, Galiè, Nazzareno, Tapson, Victor, Rubin, Lewis, Di Scala, Lilla, Tapson, Victor F., Harrison W. Farber, Lilla Di Scala, Richard N. Channick, Chin, Kelly, Preston, Ioana, Sean Gaine, Sitbon, Olivier, Kelly Chin, Victor F. Tapson, Irene M. Lang, Preiss, Ralph, McLaughlin, Vallerie V., Preston, Ioana R., Marius M. Hoeper, Olivier Sitbon, Ioana R. Preston, Hossein-Ardeschir Ghofrani   +39 more
core   +1 more source

Abstracts From PVRI 2026 Dublin

Pulmonary Circulation, Volume 16, Issue 2, April 2026.
wiley   +1 more source

Supplemental material for Real-life data on Selexipag for the treatment of pulmonary hypertension

, 2019
Supplemental Material for Real-life data on Selexipag for the treatment of pulmonary hypertension by Michaela Barnikel, Nikolaus Kneidinger, Friederike Klenner, Andrea Waelde, Paola Arnold, Torben Sonneck, Jürgen Behr, Claus Neurohr and Katrin Milger in ...
Nikolaus Kneidinger (4521751), Claus Neurohr (832616), Michaela Barnikel (6790034), Katrin Milger (2586916), Andrea Waelde (6790040), Paola Arnold (6790043), Jürgen Behr (272687), Torben Sonneck (6790046), Friederike Klenner (6790037)   +8 more
core   +1 more source

Solubilidad y disolución mejoradas de Selexipag mediante complejos de inclusión de β-ciclodextrina: formulación y evaluación

Introducción: Selexipag, es un agonista selectivo del receptor de prostaciclina (IP) utilizado en la hipertensión arterial pulmonar. Presenta baja solubilidad en agua, lo que limita su biodisponibilidad oral.
Lakshmi, Satya B., Kiran, Vema, Srimukh, Battu, Soujanya, Choudary, Vanitha, Kondi, Prasanna, Kumar Desu   +5 more
core   +1 more source

Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta‐analysis

Animal Models and Experimental Medicine
Background The maintenance dosage of selexipag is categorized as low, medium or high. In order to assess the efficacy and safety of different dosages of selexipag for the risk stratification of pulmonary arterial hypertension (PAH), we performed a ...
Shang Wang, Yi Yan, Jian Zhang, Ping Yuan, Ci‐Jun Luo, Hong‐Ling Qiu, Hui‐Ting Li, Jian Xu, Lan Wang, Tian‐Lan Li, Rong Jiang   +10 more
doaj   +1 more source

Identification of Selexipag amorphous Polymorphs and Development of an Efficient Synthetic Process for Their Preparation.

The present work describes a novel amorphous polymorphic form of Selexipag (1), a drug used for the treatment of pulmonary arterial hypertension, along with its preparation process. The compound was obtained through an improved synthetic process based on
Prashant Patil, Dattatray Chadar, Gorakshanath Shinde, Dilip Birar, Pritesh Kardile   +4 more
core   +1 more source